These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4480885)

  • 21. [Present status of the treatment of ascites in liver cirrhosis].
    Sepúlveda B; Perches A; Ramírez C
    Gac Med Mex; 1968 Feb; 98(2):206-14. PubMed ID: 5738270
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of azosemide and furosemide in ascitic patients without and during administration of spironolactone.
    Radó JP; Molnár Z; Hartai A; Gercsák G
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):532-7. PubMed ID: 7174156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diuretics.
    Havard CW
    Practitioner; 1974 Oct; 213(1276 SPEC NO):454-66. PubMed ID: 4457838
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver.
    Brunner G; von Bergmann K; Häcker W; von Möllendorff E
    Arzneimittelforschung; 1988 Jan; 38(1A):176-9. PubMed ID: 3285830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [ON THE SUBJECT OF DIURESIS WITH METOPIRONE (SU-4885)].
    CEREDA UG; FRANZINI P
    Minerva Med; 1964 Jul; 55():2335-8. PubMed ID: 14181820
    [No Abstract]   [Full Text] [Related]  

  • 26. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
    Radó JP; Sawinsky I; Juhos E
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prolonged treatment of ascitic cirrhosis by the combination of a saldiuretic and a spironolactone].
    Tolot F; Dechavannes M; Fiere D
    Lyon Med; 1966 Jan; 215(1):29-35. PubMed ID: 5904663
    [No Abstract]   [Full Text] [Related]  

  • 28. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of diuretic measures in hydropic conditions. II. Results in liver cirrhosis].
    Dürr F; Kaufmann W; Horbach L; Michaelis J; Neuhaus GA; Praetorius F
    Klin Wochenschr; 1969 Nov; 47(21):1142-51. PubMed ID: 5382003
    [No Abstract]   [Full Text] [Related]  

  • 30. Diuretics. II. Clinical considerations.
    Anderton JL; Kincaid-Smith P
    Drugs; 1971; 1(2):141-65. PubMed ID: 4939014
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of the diuretic effects of oral administration of chlorothiazide and parenteral administration of mercaptomerin.
    FAIRWEATHER MJ; LEWIS JM; CHAPMAN DW; FORD RV
    Postgrad Med; 1959 Feb; 25(2):209-14. PubMed ID: 13633648
    [No Abstract]   [Full Text] [Related]  

  • 32. [Saluretics in liver diseases].
    Dorner M; Frey G
    Munch Med Wochenschr; 1966 Dec; 108(51):2583-4. PubMed ID: 6013308
    [No Abstract]   [Full Text] [Related]  

  • 33. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
    Fernández-Esparrach G; Guevara M; Sort P; Pardo A; Jiménez W; Ginès P; Planas R; Lebrec D; Geuvel A; Elewaut A; Adler M; Arroyo V
    J Hepatol; 1997 Mar; 26(3):614-20. PubMed ID: 9075669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of clonidine and diuretic in cirrhotic ascites with activated sympathetic nervous system: Would it be a magical bullet?
    Rai RR; Jain P
    Hepatology; 2008 Jan; 47(1):360. PubMed ID: 18080335
    [No Abstract]   [Full Text] [Related]  

  • 35. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.
    Gatta A; Angeli P; Caregaro L; Menon F; Sacerdoti D; Merkel C
    Hepatology; 1991 Aug; 14(2):231-6. PubMed ID: 1860680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis.
    Applefeld JJ; Kasmer RJ; Hak LJ; Dukes GE; Wermeling DP; McClain CJ
    Aliment Pharmacol Ther; 1994 Aug; 8(4):397-402. PubMed ID: 7986964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Torasemide in the treatment of patients with cirrhosis and ascites.
    Gentilini P; Laffi G; La Villa G; Carloni V; Foschi M; Romanelli RG; Marra F
    Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():81-5. PubMed ID: 8435382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of mercurial diuresis in patients with ascites due to cirrhosis.
    HILTON JG
    Am J Med; 1952 Mar; 12(3):311-8. PubMed ID: 14902878
    [No Abstract]   [Full Text] [Related]  

  • 39. Spironolactone in heart failure--a revived role for an old drug.
    Bradley C
    Intensive Crit Care Nurs; 2000 Dec; 16(6):403-4. PubMed ID: 11091472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bumetanide, spironolactone and a combination of the two, in the treatment of ascites due to liver disease. A prospective, controlled, randomized trial.
    Sarin SK; Sachdev G; Mishra SP; Sundaram KR; Shrivastwa A; Talukdar V; Broor SL
    Digestion; 1988; 41(2):101-7. PubMed ID: 3065101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.